ABECMA is the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapies including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/X1gUSiQ
No comments:
Post a Comment